EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strategies to decrease inequalities in cancer therapeutics, care and prevention

Ulrik Ringborg, Joachim von Braun, Julio Celis, Michael Baumann iD, Anton Berns, Alexander Eggermont, Edith Heard, Manuel Heitor, Mammen Chandy, Chien-Jen Chen, Alberto Costa, Francesco De Lorenzo und 25 weitere

Molecular Oncology · 2024-02 · 18 (2) · 245-279

DOI: 10.1002/1878-0261.13575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 22.01.2024. Verfasst von Ulrik Ringborg und 36 weiteren Autor:innen. Beteiligte Einrichtung: European Academy of Cancer Sciences, Stockholm, Sweden. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Cancer Research UK, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the USA‐Cancer Moonshot and the EU‐Mission on Cancer and Europe's Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organized by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research defined as a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention modalities. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and clinical research, as for ensuring state‐of‐the‐art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost‐effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivizing research aimed at prevention and cancer therapeutics/care with an increased focus on patients' needs and cost‐effective healthcare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansVatican CityTranslational Research, BiomedicalDelivery of Health CarePrecision Medicine

Stichwörter der Autor:innen

cancer preventioncancer therapeutics/carehealthcareinequalitiesscience policytranslational cancer research

Autor:innen und Institutionen

  • European Academy of Cancer Sciences, Stockholm, Sweden.
  • Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden.
  • Pontifical Academy of Sciences, Vatican City, Italy.
  • Bonn University, Germany.
  • Danish Cancer Institute, Copenhagen, Denmark.
  • German Cancer Research Center, Heidelberg, Germany.

ORCID-Profile: Michael Baumann, Ingemar Ernberg, Rui Henrique, Mechthild Krause, Simon Oberst, M Iqbal Parker, Joachim Schüz, Eric Solary

Förderung

  • World Health Organization
  • Cancer Research UK
  • Cancerfonden

Zitieren

APA

Ringborg, U., von Braun, J., Celis, J., Baumann, M., Berns, A., Eggermont, A., Heard, E., Heitor, M., Chandy, M., Chen, C. J., Costa, A., De Lorenzo, F., De Robertis, E. M., Dubee, F. C., Ernberg, I., Gabriel, M., Helland, Å., Henrique, R., Jönsson, B., …, & Yang, H. (2024). Strategies to decrease inequalities in cancer therapeutics, care and prevention. Molecular Oncology, 18(2), 245-279. https://doi.org/10.1002/1878-0261.13575

Vancouver

Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, et al. Strategies to decrease inequalities in cancer therapeutics, care and prevention. Molecular Oncology. 2024;18(2):245-279. doi:10.1002/1878-0261.13575

BibTeX
@article{Ringborg2024,
  author = {Ringborg, Ulrik and von Braun, Joachim and Celis, Julio and Baumann, Michael and Berns, Anton and Eggermont, Alexander and Heard, Edith and Heitor, Manuel and Chandy, Mammen and Chen, Chien-Jen and Costa, Alberto and De Lorenzo, Francesco and De Robertis, Edward M and Dubee, Frederick Charles and Ernberg, Ingemar and Gabriel, Mariya and Helland, Åslaug and Henrique, Rui and Jönsson, Bengt and Kallioniemi, Olli and Korbel, Jan and Krause, Mechthild and Lowy, Douglas R and Michielin, Olivier and Nagy, Peter and Oberst, Simon and Paglia, Vincenzo and Parker, M Iqbal and Ryan, Kevin and Sawyers, Charles L and Schüz, Joachim and Silkaitis, Katherine and Solary, Eric and Thomas, David and Turkson, Peter and Weiderpass, Elisabete and Yang, Huanming},
  title = {Strategies to decrease inequalities in cancer therapeutics, care and prevention},
  journal = {Molecular Oncology},
  year = {2024},
  volume = {18},
  number = {2},
  pages = {245--279},
  doi = {10.1002/1878-0261.13575}
}
Kostenlos starten →